What is the role of lorlatinib (Lorbrena) in the treatment of non-small cell lung cancer (NSCLC)?

Updated: Aug 21, 2019
  • Author: Maurie Markman, MD, MS; Chief Editor: Keith K Vaux, MD  more...
  • Print


Lorlatinib (Lorbrena) gained accelerated FDA approval in November 2018 for ALK-positive metastatic NSCLC in patients who have progressed on crizotinib and at least 1 other ALK inhibitor, or alectinib or ceritinib as a first ALK inhibitor therapy. [38]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!